Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes

Liana K. Billings, Director of Clinical and Genetics Research in Diabetes and Cardiometabolic Disease at Endeavor Health; lead author

“Obesity and type 2 diabetes are interconnected, and we are seeing the potential benefit of targeting multiple hormonal pathways to address both”

Liana K. Billings, Director of Clinical and Genetics Research in Diabetes and Cardiometabolic Disease at Endeavor Health; lead author

“Across the dose combinations studied with eloralintide and tirzepatide, participants had substantial weight loss alongside meaningful reductions in A1C. These are outcomes that matter to patients. We need to continue building on these findings so that, in the future, we can offer patients more treatment options that address both weight and glucose and better reflect the complexity of living with type 2 diabetes and obesity.”

Kenneth Custer, Executive vice president and president of Lilly Cardiometabolic Health

“Lilly continues to pioneer new medicines for people living with obesity and diabetes, building on our scientific track record with tirzepatide, the first approved GIP and GLP-1 dual agonist, and retatrutide, our investigational triple agonist”

Kenneth Custer, Executive vice president and president of Lilly Cardiometabolic Health

“EloraTZP represents our next frontier, pairing a selective amylin receptor agonist with tirzepatide, which could be an additive and more physiological approach to managing metabolic health. We are highly encouraged by our Phase 2 results with EloraTZP and look forward to quickly initiating Phase 3 studies.”